Abstract:The Sirtuin1 agonist resveratrol could inhibit cardiomyocyte apoptosis by upregulating Mitofusin2, antagonizing oxidative stress injury, and ameliorating doxorubicin‐induced cardiotoxicity. Background Doxorubicin is a widely used cytotoxic chemotherapy agent for treating different malignancies. However, its use is associated with dose‐dependent cardiotoxicity, causing irreversible myocardial damage and significantly reducing the patient's quality of life and survival. In this study, an animal model of doxorubicin‐induced cardiomyopathy was used to investigate the pathogenesis of doxorubicin‐induced myocardial injury. This study also investigated a possible treatment strategy for alleviating myocardial injury through resveratrol therapy in vitro. Methods Adult male C57BL/6J mice were randomly divided into a control group and a doxorubicin group. Body weight, echocardiography, surface electrocardiogram, and myocardial histomorphology were measured. The mechanisms of doxorubicin cardiotoxicity in H9c2 cell lines were explored by comparing three groups (phosphate‐buffered saline, doxorubicin, and doxorubicin with resveratrol). Results Compared to the control group, the doxorubicin group showed a lower body weight and higher systolic arterial pressure, associated with reduced left ventricular ejection fraction and left ventricular fractional shortening, prolonged PR interval, and QT interval. These abnormalities were associated with vacuolation and increased disorder in the mitochondria of cardiomyocytes, increased protein expression levels of α‐smooth muscle actin and caspase 3, and reduced protein expression levels of Mitofusin2 (MFN2) and Sirtuin1 (SIRT1). Compared to the doxorubicin group, doxorubicin + resveratrol treatment reduced caspase 3 and manganese superoxide dismutase, and increased MFN2 and SIRT1 expression levels. Conclusion Doxorubicin toxicity leads to abnormal mitochondrial morphology and dysfunction in cardiomyocytes and induces apoptosis by interfering with mitochondrial fusion. Resveratrol ameliorates doxorubicin‐induced cardiotoxicity by activating SIRT1/MFN2 to improve mitochondria function.

Resveratrol Attenuates Doxorubicin-Induced Cardiomyocyte Apoptosis in Lymphoma Nude Mice by Heme Oxygenase-1 Induction

Role of HO-1 in the Protective Effect of Resveratrol on Doxorubicin-Induced Artery Endothelial Apoptosis in Lymphoma Nude Mice

Resveratrol Attenuates Doxorubicin-Induced Cardiomyocyte Apoptosis in Mice Through SIRT1-mediated Deacetylation of P53

Effect of Heme Oxygenase-1 on Protection of Myocardial Cells by Resveratrol Against Doxorubicin-Induced Apoptosis

Protective Effect of Resveratrol on Doxorubicin-Induced Artery Endothelial Apoptosis in Lymphoma Model of Nude Mice

Resveratrol Protects Against Doxorubicin-Induced Cardiotoxicity by Attenuating Ferroptosis Through Modulating the MAPK Signaling Pathway.

Resveratrol-Induced Autophagy Promotes Survival and Attenuates Doxorubicin-Induced Cardiotoxicity

Resveratrol, a Polyphenol Phytoalexin, Protects Against Doxorubicin‐induced Cardiotoxicity

Resveratrol Prevents Doxorubicin-Induced Cardiotoxicity in H9c2 Cells Through the Inhibition of Endoplasmic Reticulum Stress and the Activation of the Sirt1 Pathway.

Resveratrol Suppresses Doxorubicin-Induced Cardiotoxicity by Disrupting E2F1 Mediated Autophagy Inhibition and Apoptosis Promotion.

Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury

Low-Dose Radiation Reduces Doxorubicin-Induced Myocardial Injury Through Mitochondrial Pathways

Resveratrol Attenuates Doxorubicin-Induced Cardiotoxicity in Rats by Up-Regulation of Vascular Endothelial Growth Factor B.

Low-Dose Radiation Enhanced Inhibition of Breast Tumor Xenograft and Reduced Myocardial Injury Induced by Doxorubicin.

Long Noncoding RNA NONMMUT015745 Inhibits Doxorubicin-Mediated Cardiomyocyte Apoptosis by Regulating Rab2A-p53 Axis

Low Dose Radiation Prevents Doxorubicin-Induced Cardiotoxicity.

Liposomal Resveratrol and/or Carvedilol Attenuate Doxorubicin-Induced Cardiotoxicity by Modulating Inflammation, Oxidative Stress and S100A1 in Rats

SNX17 Protects the Heart from Doxorubicin-Induced Cardiotoxicity by Modulating LMOD2 Degradation.

Resolvin D1 Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Inflammation, Oxidative and Endoplasmic Reticulum Stress

Antiresistin Neutralizing Antibody Alleviates Doxorubicin-Induced Cardiac Injury in Mice

Resveratrol-Mediated Reversal of Doxorubicin-Induced Osteoclast Differentiation